Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
G Van Assche, W J Sandborn, B G Feagan, B A Salzberg, D Silvers, P S Monroe, W M Pandak, F H Anderson, J F Valentine, G E Wild, D J Geenen, R Sprague, S R Targan, P Rutgeerts, V Vexler, D Young, and R S Shames
Competing interests: GVA, WS, BF and PR are consultants for Protein Design Labs. GVA, WS, BF, BS, DS, PM, WP, FA, JV, GW, DG, RS, ST and PR have all received research support from Protein Design Labs. VV, DY and RS are employees of Protein Design Labs.
